Stock Analysis, Dividends, Split History

LC / LendingClub Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price3.41
Volume1,130,200.00
Market Cap ($M)1,430.56
Enterprise Value ($M)999.59
Book Value ($M)871.02
Book Value / Share2.06
Price / Book1.64
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 417,473,846
Common Shares Outstanding 417,579,735
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.17
Return on Assets (ROA)-0.03
Return on Equity (ROE)-0.16
Balance Sheet (mrq) ($M)
Assets3,949.08
Liabilities3,074.86
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues574,540,000.00
Net Income-154.04
Earnings Per Share Basic-0.38
Earnings Per Share Diluted-0.38
Cash Flow Statement (mra) ($M)
Cash From Operations-590.81
Cash from Investing933.81
Cash from Financing933.81
Identifiers and Descriptors
CUSIP52603A109
Central Index Key (CIK)1409970
Related CUSIPS
52603A909 052603A10 52603A110 52603A959 052603B10

Split History

Stock splits are used by LendingClub Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

UPDATE 3-New York sues U.S. to stop fintech bank charters

2018-09-14 reuters
NEW YORK (Reuters) - New York state’s top banking regulator on Friday sued the federal government to void its decision to award national bank charters to online lenders and payment companies, saying it was unconstitutional and put vulnerable consumers at risk. (2-0)

UPDATE 2-New York sues U.S. regulator for allowing fintech bank charters

2018-09-14 reuters
NEW YORK (Reuters) - New York state’s top banking regulator on Friday sued the U.S. Office of the Comptroller of the Currency, seeking to void its decision to begin granting national bank charters to online lenders and payment companies. (2-0)

UPDATE 1-New York regulator sues OCC for allowing fintech bank charters

2018-09-14 reuters
NEW YORK (Reuters) - New York state’s top banking regulator on Friday sued the U.S. Office of the Comptroller of the Currency, seeking to void its decision to begin granting national bank charters to financial technology companies. (2-0)

UPDATE 3-Funding Circle plans October listing in British 'fintech' first

2018-09-10 reuters
LONDON, Sept 10 (Reuters) - Funding Circle (IPO-FNIG.L) will test investor demand for British peer-to-peer lenders in a listing scheduled for October and expected to value it at more than 1.5 billion pounds ($1.94 billion). (2-0)

Tracking Chase Coleman's Tiger Global Portfolio - Q2 2018 Update

2018-09-05 seekingalpha
The largest three positions are Spotify, Amazon.com, and JD.com, and they add up to ~30% of the portfolio. (152-6)

CUSIP: 52603A109